Brimonidine topical gel

Drug Profile

Brimonidine topical gel

Alternative Names: Brimonidine tartrate gel; CD 07805/47; COL 118; Col-118; Mirvaso; Onreltea; Sansrosa; SR-101

Latest Information Update: 14 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SansRosa Pharmaceutical Development
  • Developer Galderma
  • Class Antiglaucomas; Antihypertensives; Imidazoles; Quinoxalines; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Erythema

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 12 Oct 2015 No recent reports on development identified - Phase-II for Erythema in USA (Topical, twice-daily dosing)
  • 30 Jun 2014 Galderma completes a phase II trial in Erythema (prevention) in Germany (EudraCT2013-005083-26)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top